Markman documents appear to favor Celgene, The Street says Public documents for the pre-trial Markman hearing appear to favor Celgene over Natco, the generic drugmaker challenging some of Celgene's Revlimid patents, The Street's Adam Feuerstein reports. Shares of Celgene are up 5% to $145.33 in mid-day trading. Reference Link
News For CELG From The Last 14 Days
Check below for free stories on CELG the last two weeks.